Informação da revista
Vol. 39. Núm. 4.Outubro - Dezembro 2017
Páginas 293-390
Baixar PDF
Mais opções do artigo
Vol. 39. Núm. 4.Outubro - Dezembro 2017
Páginas 293-390
Original article
DOI: 10.1016/j.bjhh.2017.05.010
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
Luiza Soares Vieira da Silvaa,
Autor para correspondência

Corresponding author at: Hematology and Oncology Department – Santa Casa Medical School, R. Dr. Cesário Mota Júnior, 112 – Vila Buarque, 01221-020 São Paulo, SP, Brazil.
, Edvan de Queiroz Crusoeb, Lais Rocha Guimarães de Souzab, Carlos Sérgio Chiattonea, Vânia Tietsche de Moraes Hungriaa
a Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil
b Hospital Universitário Professor Edgard Santos da Universidade Federal da Bahia (HUPES/UFBA), Salvador, BA, Brazil
Este item recebeu
Informação do artigo
Tabelas (2)
Table 1. Clinical and laboratory characteristics of the study population.
Table 2. Comparison of patients with and without the emergence of oligoclonal bands.
Mostrar maisMostrar menos

The emergence of oligoclonal bands, proteins differing from those originally identified at diagnosis, has been reported in multiple myeloma patients after high-dose chemotherapy followed by autologous stem cell transplantation and after successful conventional chemotherapy. The clinical relevance of oligoclonal bands remains unclear, but their emergence has been associated with better prognosis. The aim of the present study was to determine the prevalence, clinical characteristics and prognostic impact of the presence of oligoclonal bands in multiple myeloma patients.


A retrospective cohort study was conducted. The study included newly diagnosed multiple myeloma patients with at least very good partial response after conventional dose or high-dose chemotherapy followed by autologous stem cell transplantation. The emergence of oligoclonal bands was identified using serum protein electrophoresis as well as serum and urine immunofixation techniques.


A total of 101 patients were included with a median follow-up of 42 months. In total, 55% were male, and the median age was 58 years (29–87 years). Fifty-one (50.5%) patients developed oligoclonal bands. They comprised 60% (45/75) of patients treated with autologous stem cell transplantation and 23% (6/26) of those who were not transplanted. Patients with oligoclonal bands showed better progression-free survival than those without the emergence of oligoclonal bands (p-value=0.0075).


The prevalence of oligoclonal bands in this study population was 50.5% with its frequency being greater in cases treated with autologous stem cell transplantation and in those attaining complete remission. Complete remission was more important than the emergence of oligoclonal bands on progression-free survival.

Abnormal protein band
Oligoclonal bands
Multiple myeloma
Texto Completo

Multiple myeloma (MM) is a hematologic disorder that is characterized by the clonal expansion of plasma cells in the bone marrow. These plasma cells are responsible for the production of a unique monoclonal immunoglobulin with a constant isotype and light chain restriction that can be found in serum and/or urine and is termed paraprotein or the M component.1 The measurement of this monoclonal protein by serum protein electrophoresis (SPE) and immunofixation is invaluable for monitoring patients with MM.1

Since the introduction of high-dose melphalan followed by rescue using autologous hematopoietic stem cell transplantation (ASCT), the emergence of oligoclonality or oligoclonal bands (OB) has been described in numerous studies.2–9 This is defined as follows: (1) a new monoclonal component identified by SPE, (2) a variation of the immunoglobulin subtype, and/or (3) the emergence of more than one immunoglobulin subtype detected by serum or urine immunofixation that differs from the initial pattern observed at diagnosis.2–5 These invariably small components can remain undetected by SPE but are identified by immunofixation in up to 66% of cases.3

The prevalence of OB varies, ranging from 6.6% to 73%.3,6 They are commonly found in patients who have undergone ASCT.2,3,7,8 However, OB can also emerge after conventional chemotherapy, particularly following the use of the novel agents, such as immunomodulators (IMIDs) and proteasome inhibitors (PI).4,5 The presence of OB has been associated with superior response rates.2,5 While initially described as a mere transient phenomenon of immunologic recovery, some authors have suggested that the appearance of these bands is associated with improved prognosis and longer survival.2–4,9,10

The emergence of OB can be mistaken as disease progression, leading to unwarranted changes in treatment. Thus, to better understand the frequency, the clinical characteristics and the prognostic impact of OB, the clinical records and the results of SPE and immunofixation tests of MM patients who had at least very good partial response (VGPR) after treatment were analyzed. This is the first study analyzing the impact of OB in MM patients treated in Brazil.


The medical records of 328 patients who were treated at two referral centers for MM in the Brazilian national health system (Santa casa de São Paulo Hospital and University Hospital of the Universidade Federal da Bahia) from July 2003 to June 2013 were reviewed. Participants had achieved at least VGPR, defined as serum and urine M-protein detectable by immunofixation, but not by SPE, or who achieved ≥90% reduction in serum M-protein plus urine M-protein level <100mg/24h after first-line therapy,11 specifically, conventional doses of chemotherapy or high-dose chemotherapy and ASCT. A total of 101 patients were included for the identification of the emergence of OB using the SPE and immunofixation techniques. The study was approved by the Research Ethics Committees of both institutions.

The analyzed variables were sex and age at diagnosis, type of immunoglobulin secreted, Eastern cooperative oncology group (ECOG) performance status, staging systems (Durie-Salmon and International staging system – ISS), treatment (high-dose chemotherapy and ASCT or conventional chemotherapy), response assessment and emergence of OB.

The emergence of OB was defined as (1) new monoclonal spike on SPE, which differed from the initial pattern evidenced by direct comparison of assays, (2) immunoglobulin subtype switching, and/or (3) more than one immunoglobulin subtype at serum and urine immunofixation.

The response criteria were based on the 2006 International myeloma working group.11 Overall survival was calculated from the start of treatment to death or loss to follow-up and progression-free survival (PFS) was calculated from the start of treatment to progression, death or loss to follow-up.

Categorical variables were compared using the Chi-square or Fisher exact tests, the t-test was used to compare age among groups and the Kaplan–Meier curve was employed for survival analysis, with comparison across groups using the log rank test. Kaplan–Meier analyses were also used to identify potential predictor variables for PFS. These variables were included in the Cox regression model that also had the treatment group as a covariate. Statistical analyses were performed using MedCalc software (Mariakerke, Belgium, v


A total of 101 multiple myeloma patients with VGPR or better responses after conventional or high-dose chemotherapy as the first line of treatment were included. The median follow-up was 42 months (range: 7.63–131.4 months). Fifty-five (54.5%) patients were male and 46 (45.5%) were female. The median age at diagnosis was 58 (range: 29–87) years. The clinical characteristics of the study population are given in Table 1.

Table 1.

Clinical and laboratory characteristics of the study population.

Age at diagnosis – years (n=101)
Range  29–87 
Median  58 
Sex – n (%) (n=101)
Male  55 (54.5) 
Female  46 (45.5) 
ECOG – n (%) (n=101)
34 (33.7) 
18 (17.8) 
16 (15.8) 
17 (16.8) 
2 (2.0) 
Not assessed  14 (13.9) 
DS – n (%) (n=100)
2 (2.0) 
II  6 (6.0) 
III  92 (92.0) 
ISS – n (%) (n=94)
33 (35.1) 
II  30 (31.9) 
III  31 (33.0) 
M-component – n (%) (n=101)
IgA  24 (23.8) 
IgG  61 (60.4) 
IgM  1 (1.0) 
Kappa (free)  7 (6.9) 
Lambda (free)  8 (7.9) 

ECOG: Eastern cooperative oncology group; DS: Durie-Salmon; ISS: International staging system; M-component: monoclonal component.

Seventy-five patients were considered eligible for ASCT. For induction therapy, the cyclophosphamide, thalidomide and dexamethasone regimen (CTD), used in 52% of patients, was the most common treatment. This was followed by thalidomide and dexamethasone (TD) in 21.3% of patients and by vincristine, doxorubicin and dexamethasone (VAD) in 17.3% of patients. The patients who were considered ineligible for ASCT (n=26) were mainly treated with CTD (38.5%), melphalan and prednisone (23%), and melphalan, prednisone and thalidomide (MPT) (15.4%).

OB emerged in 51 (50.5%) patients, of which 54.9% were female and 45.1% were male. Despite a slight predominance of females, there was no statistically significant difference between the groups. The median age of these patients was 58 (range: 52–63) years. From the 51 cases in which OB emerged, 45 cases (88.2%) were ASCT patients, and six (11.8%) were ineligible cases. An analysis of the prevalence of OB by treatment type revealed that 60% of ASCT patients presented OB versus only 23% of transplant-ineligible patients. Achieving complete response (CR) was associated with a greater likelihood of the emergence of OB, and specifically, 62.7% of CR patients developed OB (p-value=0.03). Table 2 shows the comparison of patients with and without the emergence of OB.

Table 2.

Comparison of patients with and without the emergence of oligoclonal bands.

Characteristic  No emergence of oligoclonal bands (n=50)  Emergence of oligoclonal bands (n=51)  p-Value 
Age at diagnosis – years
Range  41–87  29.0–74.0   
Mean±SD  60.1±11.1  57.1±8.8  0.1370a 
Median (IQR)  59 (52.0–68.0)  58.0 (52.0–63.0)   
Sex – n (%)
Male  32 (64.0)  23 (45.1)   
Female  18 (36.0)  28 (54.9)  0.0878b 
ISS – n (%)
15 (32.6)  18 (37.5)   
II  16 (34.8)  14 (29.2)  0.8204b 
III  15 (32.6)  16 (33.3)   
Response – n (%)
CR  20 (40.0)  32 (62.7)  0.0368b 
VGPR  30 (60.0)  19 (37.3)   
ASCT – n (%)
No  20 (40.0)  6 (11.8)  0.0026b/0.00139c 
Yes  30 (60.0)  45 (88.2)   

SD: standard deviation; IQR: interquartile range; ISS: International staging system; CR: complete response; VGPR: very good partial response; ASCT: autologous hematopoietic stem cell transplantation.


t-Test for independent samples.


Chi-square test.


Fisher's exact test.

OB were detectable by serum or urine immunofixation, but not by SPE, in 64% of cases. The most frequent finding was the combination of more than one immunoglobulin subtype (IgG, kappa and Lambda), which was identified in 21 cases.

The median PFS for the entire group was 38.4 months. The median PFS were 45.4 and 34.7 months for patients with and without the emergence of OB, respectively [Hazard ratio (HR)=0.5249; 95% confidence interval (CI): 0.3194–0.8625; p-value=0.0075; Figure 1].

Figure 1.

Progression-free survival according to the emergence of oligoclonal bands (OB) or otherwise. (p=0.0075).

The median overall survival for the entire group was 89.9 months. Patients without the emergence of OB had a median overall survival of 80.7 months versus 89.9 months for patients with the emergence of OB (HR: 0.5291; 95% CI: 0.2293–1.2212; p-value=0.1431).

Patients with ISS 1 and the emergence of OB had a median PFS of 45.1 months, while those without the emergence of OB had a median PFS of 28.3 months (HR: 0.3720; 95% CI: 0.1505–0.9192; p-value=0.0120; Figure 2).

Figure 2.

Progression-free survival according to the emergence of oligoclonal bands (OB) in ISS1 patients (p=0.0120).

The median survival rate of patients who received ASCT and had the emergence of OB was 49.6 months, and for those without the emergence of OB the median survival rate was 32.8 months (HR: 0.4552; 95% CI: 0.2345–0.8835; p-value=0.0063; Figure 3).

Figure 3.

Progression-free survival according to the emergence of oligoclonal bands (OB) in ASCT patients (p=0.0063).

The PFS was evaluated in multivariate analysis (Cox model) using ISS (1 vs. 2/3), response rate (CR vs. VGPR), type of treatment (transplant vs. no transplant) and emergence of OB (yes vs. no) as independent variables. In the analysis of the model that included (OB, Response Rate and ISS) only OB, and CR were independent predictors for better PFS. A second model was run using high-dose chemotherapy as a fourth variable, in addition to those described before. In this second model, the emergence of OB lost its prognostic significance, and the only variable significantly associated with increased PFS was CR.


Here, we report the first Brazilian study involving the emergence of OB in MM patients after conventional chemotherapy or high-dose chemotherapy followed by ASCT. A prevalence of 50.5% of OB emerged in MM patients with VGPR or better, and the emergence of OB was more common in patients who underwent transplantation and in those who achieved CR. Previous studies reported a prevalence of the emergence of OB in transplanted patients, ranging from 5.9% to 24.5% and likewise, this study found that the rates of the emergence of OB were higher in transplanted patients.3,7,8,12 The use of novel agents in both transplant and non-transplant settings was also associated with a high prevalence of OB.4,5,13

The impact on overall survival could not be proven, possibly due to the relatively small sample size. Studies with larger sample sizes have shown longer overall survival among individuals presenting the emergence of OB.2,3,8,13 In one study involving 1942 patients, Wadhera et al.3 found significantly greater overall survival among those who developed secondary monoclonal gammopathy of undetermined significance (sMGUS) compared to those who did not (73 vs. 38 months, respectively).

In this study, PFS was superior in patients who developed OB, a finding that has been reported in previous studies assessing transplanted patients only2,9,10,13 and in studies involving patients who had undergone ASCT or not.7,12

It is well established in the literature that better response predicts superior survival.14–16 This study selected the emergence of OB among patients with better responses (at least VGPR) and even in this specific group of patients, the emergence of OB had a favorable impact on PFS. Analyzing PFS in a Cox regression model including ISS (1 vs. 2/3) and response rate (CR vs. VGPR) as well as the emergence of OB, the latter remained an independent variable to predict PFS. However, on adding the type of treatment performed (ASCT vs. no ASCT) to the model, only CR was significant even though the OB was close to the significance limit (p-value=0.07). The size of cohort could have influenced this result.

Fujisawa et al. failed to confirm improvement in survival assessing the impact of OB on subgroups with at least VGPR or CR in patients submitted to ASCT or otherwise, and similarly, no impact was found for the subgroup of patients eligible for ASCT. The authors questioned the potential prognostic factor of oligoclonality, specifically, that it might be more closely linked to better responses than to the emergence of OB per se.7

These conflicting results, both in terms of prevalence and impact on survival, are probably attributed to the heterogeneity of the studies published to date. Most studies had a retrospective design, different population sizes, different definitions of OB, frequency of SPE and immunofixation tests, and used different treatments.

The detection of these new monoclonal peaks in SPE or by immunofixation during the follow-up of MM patients can be mistaken for relapse and/or disease progression, leading to unwarranted treatment or changes in treatment. As such, the finding of oligoclonality, a small monoclonal component different from that identified at diagnosis, must be carefully interpreted and regular follow-ups should be carried out before treatment decisions are made.

The advances in the MM treatment have led to better responses. The incidence of the emergence of OB has increased and its impact on survival should be confirmed in large prospective studies.


A high prevalence of the emergence of OB was seen in patients who had at least VGPR after conventional or high-dose therapy. This frequency was greater in patients who underwent ASCT and in those with CR. CR was more important than the emergence of OB on the PFS.

Conflicts of interest

The authors declare no conflicts of interest.

R.A. Kyle,S.V. Rajkumar
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
C.S. Zent,C.S. Wilson,G. Tricot,S. Jagannath,D. Siegel,K.R. Desikan
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation
Blood, 91 (1998), pp. 3518-3523
R.K. Wadhera,R.A. Kyle,D.R. Larson,A. Dispenzieri,S. Kumar,H.M. Lazarus
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma
C. Fernández de Larrea,N. Tovar,M.T. Cibeira,J.I. Aróstegui,L. Rosiñol,M. Elena
Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents
Haematologica, 96 (2011), pp. 171-173
T. Mark,D. Jayabalan,M. Coleman,R.N. Pearse,Y.L. Wang,R. Lent
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma
Br J Hematol, 143 (2008), pp. 654-660
S. Hovenga,J.T. de Wolf,J.E. Guikema,H. Klip,J.W. Smit,C.T. Smit Sibinga
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation
Bone Marrow Transplant, 25 (2000), pp. 723-728
M. Fujisawa,K. Seike,K. Fukumoto,Y. Suehara,M. Fukaya,H. Sugihara
oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival
Cancer Sci, 105 (2014), pp. 1442-1446
J.C. Jo,D.H. Yoon,S. Kim,K. Lee,E.H. Kang,S. Jang
Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma
Ann Hematol, 93 (2014), pp. 463-469
A.J. Liu,H. Zong,G.Z. Yang,Y.H. Zhai,L.H. Li
Significance of oligoclonal bands after stem cell transplantation in multiple myeloma cases
Asian Pac J Cancer Prev, 13 (2012), pp. 1483-1486
V.H. Jimenez-Zepeda,D.E. Reece,S. Trudel,N. Franke,A. Winter,C. Chen
Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival
Leuk Lymphoma, 55 (2014), pp. 2284-2289
B.G. Durie,J.L. Harousseau,J.S. Miguel,J. Bladé,B. Barlogie,K. Anderson
International Uniform response criteria for multiple myeloma
Leukemia, 20 (2006), pp. 1467-1473
D. Zou,G. An,G. Zhu,J. Wang,L. Shi,H. Meng
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias
Biol Blood Marrow Transplant, 20 (2014), pp. 319-325
N. Tovar,C.F. de Larrea,J.I. Aróstegui,M.T. Cibeira,L. Rosiñol,M. Rovira
Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution
Haematologica, 98 (2013), pp. 1142-1146
R. Alexanian,D. Weber,S. Giralt,M. Dimopoulos,K. Delasalle,T. Smith
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
Bone Marrow Transplant, 27 (2001), pp. 1037-1043
J. Martinez-Lopez,J. Blade,M.V. Mateos,C. Grande,A. Alegre,J. García-Laraña
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
F. Gay,A. Larocca,P. Wijermans,F. Cavallo,D. Rossi,R. Schaafsma
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
Revista Brasileira de Hematologia e Hemoterapia

Receba nossa Newsletter

Opções de artigo
Política de cookies
Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos?